Compare Abeona Therapeutics Inc (ABEO) vs Gold Fields Limited (GFI) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
Abeona Therapeutics Inc vs Gold Fields Limited — how do they compare? Abeona Therapeutics Inc trades at $6.74 (market cap $373.32M), while Gold Fields Limited trades at $32.76 (market cap $30.01B). The key difference: Gold Fields Limited is far larger — about 80.4× Abeona Therapeutics Inc's market cap, and Gold Fields Limited pays a 6.91% dividend while Abeona Therapeutics Inc pays none. Which is the better fit depends on your goals.
| ABEO | GFI | |
|---|---|---|
Market Cap | $373.32M | $30.01B |
Sector | Health | Basic Materials |
52-Week High | $7.23 | $61.52 |
52-Week Low | $4.17 | $23.36 |
Enterprise Value | $228.22M | $31.46B |
Dividend Yield | — | 6.91% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ABEO trades at $6.31, down 1.41% today, with a bullish technical outlook supported by moving averages. The company reported Q1 2026 results with revenue growth and beat EPS expectations, while maintaining strong profitability margins. Recent news highlights expansion of treatment centers and new cell therapy licensing.
Outlook remains positive with analyst consensus favoring Buy ratings (66.67%), though high RSI indicates potential near-term overbought conditions. Key risks include negative operating cash flow and reliance on new treatment adoption. Upside depends on continued commercial execution and pipeline advancements.
Gold Fields (GFI) trades at $33.58, down 5.3% over 24 hours, reflecting recent bearish technical momentum. The stock shows strong fundamentals with a P/E of 8.78 and robust profitability margins, including a 40.76% net income margin. Recent earnings have been mixed, with a Q1 2025 beat but subsequent misses. Cash flow improved significantly in 2025, and the balance sheet remains solid despite rising debt levels. Analyst sentiment is divided with a 44% buy rating amid operational challenges and gold price volatility.
The outlook for GFI hinges on execution at key mines like Salares Norte and gold price stability. Upside potential exists from strong cash generation and shareholder returns, but risks include cost inflation and geopolitical pressures. The current valuation appears attractive if operational targets are met, though near-term volatility may persist.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abeona Therapeutics Inc
Abeona Therapeutics develops gene and cell therapies for rare diseases. Its lead product, ZEVASKYN, is an FDA-approved therapy for recessive dystrophic epidermolysis bullosa (RDEB), a severe and life-threatening genetic skin disorder.
Read more on ABEO →About Gold Fields Limited
Gold Fields Ltd is a producer of gold and is a holder of gold reserves and resources in South Africa, Ghana, Australia and Peru. In Peru, the company also produces copper. The company is primarily involved in underground and surface gold and surface copper mining and silver and related activities, including exploration, extraction, processing and smelting. It conducts underground and surface mining operations at St. Ives, underground-only operations at Agnew, Granny Smith and South Deep and surface-only open pit mining at Damang, Tarkwa and Cerro Corona. The company's revenues are derived from the sale of gold that it produces.
Read more on GFI →
